New Therapeutics Approach in gastroenterology. Abou Rached Antoine, MD, MBAIP

Size: px
Start display at page:

Download "New Therapeutics Approach in gastroenterology. Abou Rached Antoine, MD, MBAIP"

Transcription

1 New Therapeutics Approach in gastroenterology Abou Rached Antoine, MD, MBAIP

2 Helicobacter pylori is a Gramnegative, microaerophilic, spiral-shaped bacterium Major cause of Chronic Gastritis PUD Colonizes Stomach 30%-80% Sero-prevalence affects CV, Respiratory, Autoimmu ne Treat in PIDA & ITP Helicobacter pylori 1994 WHO Class I carcinogen/definite MALToma, Adenocarcinoma

3 Prevalence of H. pylori infection 14-46% 81% 85% 88% 37-50% 27% 80% 43% 58% 63% 68% 90% 80% 918 million people 80% 60-70% 80% 80% 5-30% 824 million people 15-38% 36-73%

4 INDICATIONS FOR DIAGNOSING AND TREATING H. PYLORI INFECTION? Established Active peptic ulcer disease History of peptic ulcer disease (not treated) Gastric MALT lymphoma (low grade) After endoscopic resection of early gastric cancer Uninvestigated dyspepsia Controversial Nonulcer dyspepsia GERD Persons using NSAID Unexplained iron deficiency anemia Populations at higher risk for gastric cancer

5 Diagnosis of H. Pylori I. Diagnostic non-invasive tests II. Diagnostic invasive tests

6 Diagnostic Testing for H. pylori: noninvasive tests Non-endoscopic Testing Advantages Disadvantages Antibody testing Inexpensive, widely available, very good NPV/PPV dependent upon H. pylori prevalence. Not recommended after H. pylori therapy Urea breath tests Identifies active H. pylori infection. Excellent PPV and NPV Useful before and after therapy Reimbursement and availability remain inconsistent Fecal antigen test Identifies active H. pylori infection. Excellent PPV & NPV regardless of H. pylori prevalence. Useful before and after H pylori therapy Polyclonal test less validated than UBT in post-treatment. Monoclonal test reliable before and after antibiotic therapy.

7 Endoscopy-Based Testing for H. pylori Endoscopic testing Advantage Disadvantage Histology Excellent sensitivity and specificity Expensive and requires infrastructure and trained personnel Rapid urease testing Inexpensive and provides rapid results. Excellent specificity and very good sensitivity in properly selected patients Sensitivity significantly reduced in the Post-treatment setting Culture Excellent specificity. Allows determination of antibiotic sensitivities Expensive, difficult to perform, and not widely available. Only marginal sensitivity PCR Excellent sensitivity and specificity. Allows determination of antibiotic sensitivities Methodology not standardized across laboratories and not widely available

8 Diagnostic Testing for H. pylori: Advantages of Serology Not affected by local changes in the stomach The bacterial load can be decreased under the threshold of detection with the other methods: transitorily, in case of antimicrobial or antisecretory drugs consumption permanently in case of premalignant & malignant lesions Antibodies (CagA antibodies) remain elevated for months-years after H. pylori disappearance in the stomach

9 Treatment Regimens Triple therapy Quadruple therapy Sequential Classic therapy (7-14d): Amoxicillin, Clarithromyci n, PPI Clarithromycin, metronid azole, PPI Amoxicillin, levofloxacin, PPI Bismuth Based: Tetracycline, bismuth, m etronidazole, PPI (10 days) Non-bismuth based: Clarithromycin, metroni dazole, amoxicillin, PPI (10days) 5 days: PPI + Clarithromycin 5 days: amoxicillin, metronidaz ole +PPI

10 Primary resistance to clarithromycin (%) Failure rate of triple therapy: 69.5% if clarithromycin resistance 25% if metronidazol e resistance Eradication rate after triple therapy (%) *Fischbach L, et al. Aliment Pharmacol Ther 2007; 26(3): ; **. Mégraud F. Gut 2004; 53(9): ; ***. Sasaki M, et al. J Clin Biochem Nutr 2010; 47(1):53-8.

11 Rate of Primary Clarithromycin Resistance in H. Pylori in Europe ( )

12 Maastricht IV: Treatment recommendation

13 How to improve the standard triple therapy? Use high dose PPI: twice daily Increase the duration of the therapy from 7 to days will increase the eradication rate by 5% PPI-clarithromycin-metronidazole (PCM) and PPIclarithromycin-amoxicillin (PCA) regimens are equivalent. Certain probiotics and prebiotics show promising results as an adjuvant therapy in reducing side effects. PPI-clarithromycin containing therapies do not need to be adapted to patient factors except for dosing

14 Second line therapy After failure of PPI Clarithromycin containing therapy either: Bismuth based quadruple therapy OR Levofloxacin based triple therapy (take into account rising resistance to fluoroquinolone) After failure of second-line therapy, treatment should be guided by antimicrobial susceptibility testing whenever possible.

15 High Clarithromycin-Resistant area In areas of high clarithromycin resistance, bismuth-containing quadruple therapies are recommended for first-line empirical treatment. If this regimen is not available sequential therapy or a non-bismuth quadruple therapy is recommended. Evidence Level: 1a Grade of Recommendation: A

16 Second and Third Line In areas of high clarithromycin resistance after failure of bismuth-containing quadruple therapy: Levofloxacin containing triple therapy is recommended. Rising rates of levofloxacin resistance should be taken into account After failure of second-line therapy, treatment should be guided by antimicrobial susceptibility testing whenever possible.

17 Treatment Algorithm: Maastricht IV 1 st line 2 nd line 3 rd line

18 ACG ACG Treatment Algorithm Recommendation

19 Hepatitis B

20 The global impact of HBV disease 2 billion with evidence of HBV infection 25 40% die of cirrhosis or liver cancer World population ~6 billion million with chronic hepatitis B WHO, Fact sheet No. 204; CDC, Viral hepatitis B fact sheet; Conjeevaram HS, Lok AS. J Hepatol. 2003;38:S Lee WM. N Engl J Med. 1997;337: Lok AS. N Engl J Med. 2002;346:1682-3

21 Epidemiology Worldwide Prevalence of Hepatitis B World prevalence of HBV carriers HBsAg carriers prevalence <2% 2-7% 8% poorly documented WHO 2003.

22 Transmission of HBV Vertical (perinatal) transmission Horizontal transmission 90% of infected infants become chronically infected Mother Host 6% of people infected over the age of 5 become chronically infected Infant Recipient Child-to-child Contaminated needles Sexual contacts Healthcare worker Blood transfusion CDC Viral hepatitis B fact sheet; Lee. N Engl J Med. 1997;337: ; Lavanchy. J Viral Hepat. 2004;11:97-107

23 Epidemiology of hepatitis B and C in general population in Lebanon Prospective study: January 2010 December 2011 Screening of the general population in different regions for hepatitis B and hepatitis C

24 Epidemiology of hepatitis B and C in Results: general population in Lebanon Over 2 year period: 31,137 individuals screened ( 0.7% of population) Sex: 51% male 49% female Mean age: Male: 37.1 (range 5-89) Female: 38.4 (range 8-85)

25 Epidemiology of hepatitis B in general population in Lebanon Results: Prevalence of hepatitis B: 1.69% (542 patients HBsAg positive) Sex Ratio: M/F: 1.38 Male: 58% Female: 42% District distribution: Beirut: 0.73% Mount Lebanon: 1.79% South: 1.9% Bekaa Valley (East): 1.23% North: 1.7%

26 Indications for Treatment of HBV Infection Upon Diagnosis Phase of Chronic HBV Infection HBeAg Status HBV DNA Elevated? ALT Level Elevated? Treatment Indicated? Immune tolerant Positive Yes No No Immune active/clearance Positive/negative Yes Yes Yes Inactive carrier No No No No Reactivation Yes Yes Yes Yes

27 AASLD and EASL Recommendations for the Management of Chronic HBV Infection HBeAg-Positive Patients AASLD HBV DNA >20,000 IU/mL and ALT >2 x ULN a : consider treatment after 3 to 6 months of observation with absence of spontaneous loss of HBeAg HBV DNA >20,000 IU/mL and ALT 2 x ULN, and age >40 years or family history of HCC: consider liver biopsy and treat if significant histologic disease is present EASL HBV >2000 IU/mL and/or ALT >ULN: consider liver biopsy (or noninvasive markers) and treat if moderate to severe histologic disease is present HBeAg-Negative Patients AASLD HBV DNA >2000 IU/mL and ALT >2 x ULN: consider treatment HBV DNA >2000 IU/mL and ALT >ULN: consider liver biopsy and treat if significant histologic disease is present EASL HBV >2000 IU/mL and/or ALT >ULN: Consider liver biopsy (or noninvasive markers) and treat if moderate to severe histologic disease is present Cirrhotic Patients AASLD Compensated cirrhosis HBV DNA >2000 IU/mL: treat HBV DNA <2000 IU/mL and ALT >ULN: consider treatment Decompensated cirrhosis Treat with any detectable HBV DNA level EASL Compensated cirrhosis and decompensated cirrhosis Treat regardless of the HBV DNA level

28 Antiviral Agents Approved for the Treatment of Chronic HBV Infection Oral Antiviral Agents Drug Dose a Lamivudine: pill or oral solution Entecavir: pill or oral solution Telbivudine: pill Adefovir dipivoxil: pill Tenofovir disoproxil fumarate: pill or oral solution 100 mg, once daily 0.5 mg, once daily 600 mg, once daily 10 mg, once daily 300 mg, once daily Injection Immunostimulators Drug Dose Interferon alfa-2b Pegylated interferon alfa-2a 10 million units by SC injection 3 times/wk for wk 180 μg by SC injection weekly for 48 wk

29 Cumulative Annual Incidence of Resistance of Nucleos(t)ide Analogs

30 Antiviral resistance increases over time Lamivudine 1 Telbivudine 4 40 Incidence of resistance (%) 5% Adefovir 2 Entecavir (LAM-resistant) 3 Entecavir (naive) 3 *** 12% 24% 15% 20% 11% 0.1% 0% 0.3% 2% 0.4% 0.8% Year 1 Year 2 Year 3 Resistance to NAs is it just a matter of time?? 42% 25% 53% 40% 18% Year 4 70% 29% 65% Year 5 1 Lai, Clin Infect Dis 2003; 2 Westland, Hepatology 2003; 3 Colonno R, EASL 2007; 4 Gane, EASL 2006 Slide 25

31 Hepatitis C

32

33 Epidemiology of Hepatitis C in General Population in Lebanon Results: Prevalence of hepatitis C: 0.2% (HCV Ab positive) Sex Ratio: M/F: 0.85 PCR HCV: Male: 46% Female: 54% Positive: 84.6% Negative: 15.4%

34 Hépatite virale C

35 virale hepatitis C Futur of the concept new molecules Triple therapy Pegylated Interferon + Ribavirine + telaprevir Pegylated Interferon + Ribavirine + Boceprevir Vaccin against hépatitis C

36

37 Response-guided therapy algorithm for boceprevir

38

39

40 Response-guided therapy algorithm for telaprevir.

41

42

43

44 Classes of drugs in development for hepatitis C Drug class Mechanism of action Advantages Disadvantages NS3/4A protease inhibitors First generation NS3/4A protease involved in posttranslation processing of HCV polyproteins Potent inhibitors of HCV genotype 1 Low genetic barrier to resistance Cross-resistance is extensive between different compounds in class Drug interactions (CYP) Second generation NS3/4A protease involved in posttranslation processing of HCV polyproteins Pan-genotypic antiviral activity Higher genetic barrier to resistance than first-generation PIs; activity against many substitutions that cause resistance in first-generation PIs NS5B polymerase inhibitors NS5B RdRp is required for copying HCV-RNA genome and transcribing mrna Nucleoside inhibitors Analogs of natural substances; bind active site of RdRp; terminate viral RNA chain generation High barrier for resistance Pan-genotypic Fewer in pipeline Non-nucleoside inhibitors Bind various allosteric sites, inducing conformational change in polymerase Multiple target sites identified Low/medium antiviral efficacy Active against genotype 1 Low genetic barrier HCV genotype-/subtypedependent NS5A inhibitors Bind domain I of NS5A protein, exact role in viral replication is unclear High potency Potential activity against multiple genotypes Low genetic barrier to resistance Cyclophilin Inhibitors Target host cyclophilin enzyme; functional regulator of HCV replication Good potency Pan-genotypic High barrier to resistance Drug interactions

45 Hepatitis C virus direct-acting antiviral therapy agents in clinical development in phases II/III clinical trials NS3/NS4A protease inhibitors Phase 2 Phase 3 Licensed First generation Danoprevir/r* (RG7227) Sovaprevir (ACH-1625) GS-9256 GS-9451 ABT-450/r* Vaniprevir (MK7009) Simeprevir (TMC435) Faldaprevir (BI201335) Asunaprevir (BMS ) Boceprevir Telaprevir Second generation MK-5172 NS5B polymerase inhibitors Nucleos(t)ide analogs Mericitabine (RG7128); IDX-184 PSI-7851 Sofosbuvir (GS-7977) Non-nucleos(t)ide analogs VX-222 BMS ABT-333 ABT-072 Setrobuvir(ANA598) BI Filibuvir IDX375 VCH-916 [tegobuvir (GS-9190)] NS5A inhibitors ABT-267 GSK GS-5885 Daclatasvir (BMS ) Cyclophilin NIM-811; SCY-635 [Alisporivir]

46 Future There are many potential therapeutic options for treatment It is not yet clear whether there will be a single major treatment option used for all genotypes of HCV or whether there will be an individualized therapeutic approach that considers viral genotype, IL28B genotype, resistance mutations other factors in planning a treatment for each patient. there may be a truly realizable goal of providing curative management for the majority of patients with HCV who are treated

Treatment of Helicobacter pylori Infection

Treatment of Helicobacter pylori Infection Treatment of Helicobacter pylori Infection Epidemiology of H. pylori infection (North America) Which are the high risk groups? Epidemiology of H. pylori infection (North America) Which are the high risk

More information

Interferon-based and interferon-free new treatment options

Interferon-based and interferon-free new treatment options Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt

More information

Antiviral agents in HCV

Antiviral agents in HCV Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million

More information

Helicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.

Helicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35. An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology

More information

Hepatitis C: Aplicaciones Clínicas de la Resistencia. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña

Hepatitis C: Aplicaciones Clínicas de la Resistencia. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña Hepatitis C: Aplicaciones Clínicas de la Resistencia Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña DAA agents approved or in more advanced stages of clinical

More information

The HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany

The HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany : Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained

More information

Cornerstones of Hepatitis B: Past, Present and Future

Cornerstones of Hepatitis B: Past, Present and Future Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related

More information

HCV eradication with direct acting antivirals (DAAs)?

HCV eradication with direct acting antivirals (DAAs)? HCV eradication with direct acting antivirals (DAAs)? Emilie Estrabaud Service d Hépatologie et INSERM UMR1149, AP-HP Hôpital Beaujon, Paris, France. emilie.estrabaud@inserm.fr HCV eradication with direct

More information

29th Viral Hepatitis Prevention Board Meeting

29th Viral Hepatitis Prevention Board Meeting 29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION

More information

Direct acting anti-virals: the near future

Direct acting anti-virals: the near future Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should

More information

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division

More information

Management of Chronic Hepatitis B in Asian Americans

Management of Chronic Hepatitis B in Asian Americans Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,

More information

Chronic Hepatitis B: management update.

Chronic Hepatitis B: management update. Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)

More information

EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor

More information

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic

More information

Vicente Soriano Department of Infectious Diseases

Vicente Soriano Department of Infectious Diseases Predictors of Response to Hepatitis C Therapy Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain Diagnosis Therapy IL28B alleles Non-invasive liver fibrosis methods Viral

More information

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph

More information

Case #1. Pharmacology and Drug Interactions of Newer Direct-Acting Antivirals

Case #1. Pharmacology and Drug Interactions of Newer Direct-Acting Antivirals Pharmacology and Drug Interactions of Newer Direct-Acting Antivirals Charles W. Flexner, MD Professor of Medicine, Pharmacology, and International Health The Johns Hopkins University School of Medicine

More information

The Egyptian Plan to Cure HCV

The Egyptian Plan to Cure HCV The Egyptian Plan to Cure HCV Gamal Esmat Professor of Endemic Medicine & Hepatology Vice President of Cairo University for Graduate Studies and Research Disclosure Advisory Committee Board Member : MSD,

More information

Associate Professor of Medicine University of Chicago

Associate Professor of Medicine University of Chicago Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death

More information

Who to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat

Who to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor

More information

Hepatitis C Resistance Associated Variants (RAVs)

Hepatitis C Resistance Associated Variants (RAVs) Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure

More information

Hepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013

Hepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections

More information

Interferon Side Effects and The Future of Interferon Sparing Regimens. Todd Wills, MD ETAC Infectious Disease Specialist

Interferon Side Effects and The Future of Interferon Sparing Regimens. Todd Wills, MD ETAC Infectious Disease Specialist Interferon Side Effects and The Future of Interferon Sparing Regimens Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL FEBRUARY 15,

More information

Hepatitis C Emerging Treatment Paradigms

Hepatitis C Emerging Treatment Paradigms Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,

More information

HBV/HCV Eradication. Prof. Jean-Michel Pawlotsky, MD, PhD

HBV/HCV Eradication. Prof. Jean-Michel Pawlotsky, MD, PhD HBV/HCV Eradication Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est

More information

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route

More information

Evolution of Therapy in HCV

Evolution of Therapy in HCV Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR

More information

Hepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019

Hepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019 Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral

More information

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis

More information

Clinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline

Clinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline Clinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline Anita Mathias, PhD Clinical Pharmacology, Gilead Sciences 14 th Int. Workshop on Clinical Pharmacology of HIV Therapy April

More information

Resistencias & Epidemiología. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña

Resistencias & Epidemiología. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña Resistencias & Epidemiología Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña Rapid Evolution of HCV Regimens: Easier to take/tolerate, Short Duration, Pangenotypic,

More information

The Pipeline of New HCV Therapies: What to Expect in the Next 5 Years. Nancy Reau, MD Associate Professor University of Chicago

The Pipeline of New HCV Therapies: What to Expect in the Next 5 Years. Nancy Reau, MD Associate Professor University of Chicago The Pipeline of New HCV Therapies: What to Expect in the Next 5 Years Nancy Reau, MD Associate Professor University of Chicago Learning Objectives Upon completion of this presentation, learners should

More information

New Therapeutic Strategies: Polymerase Inhibitors

New Therapeutic Strategies: Polymerase Inhibitors New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2

More information

The Impact of HBV Therapy on Fibrosis and Cirrhosis

The Impact of HBV Therapy on Fibrosis and Cirrhosis The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for

More information

Les Inhibiteurs de Protéase du VHC

Les Inhibiteurs de Protéase du VHC Les Inhibiteurs de Protéase du VHC Pr Jean-Michel Pawlotsky National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est

More information

NUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.

NUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from

More information

Hepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology

Hepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History

More information

Basics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology

Basics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers

More information

Azienda ULSS12 Veneziana

Azienda ULSS12 Veneziana Azienda ULSS12 Veneziana Risultati del trattamento dei monoinfetti con Sofosbuvir, Simeprevir nella coorte veneziana. Confronto di esito con la coorte del trattamento con Boceprevir e Telaprevir Dr.ssa

More information

Experience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona

Experience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir

More information

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology

More information

NH2 N N N O N O O P O O O O O

NH2 N N N O N O O P O O O O O N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects

More information

American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection

American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection American Journal of Gastroenterology ISSN 0002-9270 C 2007 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2007.01393.x Published by Blackwell Publishing American College of Gastroenterology

More information

Pharmacologic Considerations when using DAAs in Cirrhosis

Pharmacologic Considerations when using DAAs in Cirrhosis Pharmacologic Considerations when using DAAs in Cirrhosis Jennifer J. Kiser, PharmD Assistant Professor University of Colorado Denver 1 st International Workshop on the Optimal Use of DAAs in Liver Transplant

More information

Introduction. The ELECTRON Trial

Introduction. The ELECTRON Trial 63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver

More information

Chronic Hepatitis B Infection

Chronic Hepatitis B Infection Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis

More information

Protease inhibitor based triple therapy in treatment experienced patients

Protease inhibitor based triple therapy in treatment experienced patients Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber

More information

HCV Case Study. Treat Now or Wait for New Therapies

HCV Case Study. Treat Now or Wait for New Therapies HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented

More information

Hepatitis B in Africa: Epidemiology, Pathophysiology and Challenges

Hepatitis B in Africa: Epidemiology, Pathophysiology and Challenges Gilead-sponsored symposium at the 11th INTEREST Workshop 2017 Hepatitis B in Africa: Epidemiology, Pathophysiology and Challenges Ponsiano Ocama Department of Medicine Makerere University College of Health

More information

Hepatitis B Treatment Pearls. Agenda

Hepatitis B Treatment Pearls. Agenda Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,

More information

ABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1

ABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1 ABCs of Hepatitis C: What s New ACG Postgraduate Course Washington, DC October 30, 2011 Ira M. Jacobson, M.D. Vincent Astor Professor of Medicine Chief, Division of Gastronterology and Hepatology Medical

More information

Management of chronic hepatitis B : recent advance in the treatment of antiviral resistance

Management of chronic hepatitis B : recent advance in the treatment of antiviral resistance anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과

More information

HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But

HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,

More information

Acute Hepatitis B Virus Infection with Recovery

Acute Hepatitis B Virus Infection with Recovery Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis

More information

MANAGEMENT OF HBV & HCV INFECTION---SIMILARITIES & DISSIMILARITIES---PAST AND PRESENT. Professor Salimur Rahman

MANAGEMENT OF HBV & HCV INFECTION---SIMILARITIES & DISSIMILARITIES---PAST AND PRESENT. Professor Salimur Rahman MANAGEMENT OF HBV & HCV INFECTION---SIMILARITIES & DISSIMILARITIES---PAST AND PRESENT Professor Salimur Rahman Department of Hepatology, BSMMU President, Association for the study of the liver, Dhaka,

More information

Hepatitis C Management and Treatment

Hepatitis C Management and Treatment Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause

More information

Hepatitis C in HIV-infected Persons. Andrea Cox, MDPhD, Ashwin Balagopal, MD

Hepatitis C in HIV-infected Persons. Andrea Cox, MDPhD, Ashwin Balagopal, MD Hepatitis C in HIV-infected Persons Andrea Cox, MDPhD, Ashwin Balagopal, MD Case 1 45 year old Caucasian man with HIV, CD4+ lymphocyte 756/mm 3 HIV RNA undetectable presents for routine follow up with

More information

Treating HCV Genotype 2 & 3

Treating HCV Genotype 2 & 3 Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: helicobacter_pylori_testing 01/01/2019 N/A 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description

More information

Case. 63 year old woman now with:

Case. 63 year old woman now with: Case 63 year old woman now with: HCV GT 1b, HCV RNA 6.2 x 10 6 IU/mL Asymptomatic except for fatigue Normal exam ALT 72 IU/mL, Bili 0.9 mg/dl, INR 1.1, Albumin 3.9 g/dl, Creatinine 0.7 mg/dl Normal EGD

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Adherence, to bismuth quadruple therapy, 543 546 Adjuvant therapy, probiotics as, 567 569 Age factors, in gastric cancer, 611 612, 616 AID protein,

More information

North Africa) The prevalence of CHB varies widely across EMEA (Europe, Middle East & 8% High 2 8% Intermediate <2% Low

North Africa) The prevalence of CHB varies widely across EMEA (Europe, Middle East & 8% High 2 8% Intermediate <2% Low The prevalence of CHB varies widely across EMEA (Europe, Middle East & North Africa) 8% High 2 8% Intermediate

More information

Hepatitis B. Epidemiology and Natural History and Implications for Treatment

Hepatitis B. Epidemiology and Natural History and Implications for Treatment Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco

More information

Tenofovir as a drug of choice for the chronic hepatitis B treatment

Tenofovir as a drug of choice for the chronic hepatitis B treatment EASL endorsed conference White Nights of Hepatology 2013 Symposium Perspectives of chronic viral hepatitis B and C treatment June 6-7 Saint-Petersburg Tenofovir as a drug of choice for the chronic hepatitis

More information

EASL and The Future of HCV Treatment

EASL and The Future of HCV Treatment EASL and The Future of HCV Treatment Douglas T. Dieterich, M.D Professor of Medicine Division of Liver Diseases, Gastroenterology and Infectious Diseases Department of Medicine Mount Sinai School of Medicine

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young

More information

Dr Janice Main Imperial College Healthcare NHS Trust, London

Dr Janice Main Imperial College Healthcare NHS Trust, London BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE

More information

Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師

Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師 Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師 Hp : Helicobacter pylori Part 1. Pathophysiology and immune response Pathogenesis of Hp infection Part 2. Clinical manifestation Part 3. Dx tests for

More information

Update on Hepatitis B and Hepatitis C

Update on Hepatitis B and Hepatitis C Update on Hepatitis B and Hepatitis C Catherine Stedman Department of Gastroenterology, Christchurch Hospital and University of Otago, Christchurch Disclosures I have the following financial relationships

More information

Helicobacter pylori: Diagnosis, treatment and risks of untreated infection

Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb

More information

Hepatitis C Treatment 2014

Hepatitis C Treatment 2014 Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype

More information

The natural course of chronic HBV infection can be divided into four, which are not always continuous.

The natural course of chronic HBV infection can be divided into four, which are not always continuous. HEPATITIS B Hepatitis B is a major global health problem. The WHO reports that there are 350 million carriers worldwide. This disease is the leading cause of liver cancer in the world and frequently leads

More information

HCV Resistance Associated variants: impact on chronic hepatitis C treatment

HCV Resistance Associated variants: impact on chronic hepatitis C treatment HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young

More information

Future strategies with new DAAs

Future strategies with new DAAs Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks

More information

Novedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona

Novedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir

More information

entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd

entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has

More information

HBV Diagnosis and Treatment

HBV Diagnosis and Treatment HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA

More information

2017 UnitedHealthcare Services, Inc.

2017 UnitedHealthcare Services, Inc. UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,

More information

The HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)

The HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1) Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell

More information

Landmarks for Prevention and Treatment

Landmarks for Prevention and Treatment HBeAg-positive chronic hepatitis B Why do I treat my patient with a nucleos(t)ide analogue? Dr. Nancy Leung BSc(Lon) MSc(Lon) MBBS(Lon) MD(Lon), FRCP(Lon) FRCP(Edin) FHKCP FHKAM Consultant Physician, Alice

More information

New developments in HCV research and their implications for front-line practice

New developments in HCV research and their implications for front-line practice New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013

More information

The Changing World of Hepatitis C

The Changing World of Hepatitis C The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures

More information

-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual

-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual 2013: HCV Genome -HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual proteins are released from polyprotein

More information

Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe

Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs 1 Division of Gastroenterology UC San Diego School of Medicine Clinical presentations of Helicobacter pylori infection

More information

Viral Hepatitis Update. Andrew Scanga, M.D. Assistant Professor of Medicine September 12 th 2015

Viral Hepatitis Update. Andrew Scanga, M.D. Assistant Professor of Medicine September 12 th 2015 Viral Hepatitis Update Andrew Scanga, M.D. Assistant Professor of Medicine September 12 th 2015 Outline Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Hepatitis A Identified in 1973 RNA virus

More information

Minimum costs to produce Hepatitis C Direct Acting Antivirals

Minimum costs to produce Hepatitis C Direct Acting Antivirals Minimum costs to produce Hepatitis C Direct Acting Antivirals Andrew Hill and Saye Khoo, Department of Pharmacology and Therapeutics, Liverpool University, UK Bryony Simmons, Imperial College, London,

More information

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research

More information

IFN-free therapy in naïve HCV GT1 patients

IFN-free therapy in naïve HCV GT1 patients IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,

More information

Hepatitis B and D Update on clinical aspects

Hepatitis B and D Update on clinical aspects Hepatitis B and D Update on clinical aspects B. Müllhaupt Gastroenterology and Hepatology Swiss Transplant and HPB-Center University Hospital Zurich beat.muellhaupt@usz.ch B.M. 11.11.17 Hepatitis Strategy

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Hepatitis B virus and solid organ transplantation Prof. Hakan Leblebicioglu Department of Clinical Microbiology and Infectious Diseases Ondokuz Mayis University, Samsun, Turkey Conflict of interest Outline

More information

Recent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov

Recent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov EASL endorsed conference White Nights of Hepatology 2012 Adverse events during antiviral therapy: how to predict, manage and monitor June 7-8 Saint-Petersburg Recent achievements in the treatment of hepatitis

More information

Outline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018

Outline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018 Outline Updates in the Clinical Management of Hepatitis B and C Jennifer C. Lai, MD, MBA Transplant Hepatologist Associate Professor of Medicine In Residence University of California, San Francisco Initial

More information

Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015

Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015 THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook

More information

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &

More information

Disclosures. Co-founder and Chief Science Officer, TechLab

Disclosures. Co-founder and Chief Science Officer, TechLab H. pylori testing Disclosures Co-founder and Chief Science Officer, TechLab Learning Objectives Evaluate the appropriate testing methodology by balancing performance, economics, and workflow. Discuss the

More information

GAZETTE COMMON GROUND. CHB: A significant and prevalent disease in the US and worldwide. Inside. Screening, diagnosis, and evaluation

GAZETTE COMMON GROUND. CHB: A significant and prevalent disease in the US and worldwide. Inside. Screening, diagnosis, and evaluation VOL III/III COMMON GROUND GAZETTE Inside CASE 1: Screening, diagnosis, and evaluation P. 1 CASE 2: Initiating treatment P. 4 CASE 3: Managing antiviral resistance P. 5 CASE 4: Achieving the maximum effect

More information

Stick or twist management options in hepatitis C

Stick or twist management options in hepatitis C Stick or twist management options in hepatitis C Dr. Chris Durojaiye & Dr. Matthijs Backx SpR Microbiology and Infectious Diseases University Hospital of Wales, Cardiff Patient history 63 year old female

More information

New Treatments for Chronic Hepatitis C. Rafael Esteban Hospital Valle Hebron. Barcelona Spain

New Treatments for Chronic Hepatitis C. Rafael Esteban Hospital Valle Hebron. Barcelona Spain New Treatments for Chronic Hepatitis C Rafael Esteban Hospital Valle Hebron. Barcelona Spain The present: a complex treatment with a better SVR Genotype 1 Genotypes 2 and 3 Triple therapy Boceprevir (BOC)

More information